secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009326
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen updates pipeline; cash $75.8M, net loss improves; SZN-043 and SZN-1326 timelines
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $75.8M at Dec 31, 2022, down from $123.5M; runway into H2 2024.
- Collaboration revenue $12.5M from Boehringer Ingelheim deal; net loss improved to $36.0M from $54.6M in 2021.
- SZN-043: Phase 1a in chronic liver disease enrolled first patient, data expected end 2023; Phase 1b in severe alcoholic hepatitis in 2024.
- SZN-1326: expect to re-initiate Phase 1a in healthy volunteers mid-2023 with lower dose; Phase 1b UC data H2 2024.
- Boehringer partnership for SZN-413: potential $10M milestone upon lead candidate nomination by end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023009326/0000950170-23-009326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023009326/srzn-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer